CLYM

Healthcare

Climb Bio, Inc.

Fundamentals6.0

Price Action5.0

News Sentiment0.0

AI Rating

5.0

Key Drivers

Strong Liquidity
Ongoing Losses
Equity Dilution

AI
AI Summary

5.0

CLYM is a well-funded but highly speculative clinical bet: its cash runway supports development, yet the ~$804M valuation and likely dilution leave little room for failure unless budoprutug delivers durable, differentiated ITP efficacy in future data—making investors best served by waiting for stronger dose-response and durability validation.

ClinicalCatalyst

DilutionRisk

Biotech‍

Price Chart

Loading chart...

Financial Metrics

Revenue (TTM)

Net Income (TTM)

EPS (Q)

MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

•Strong Liquidity
•Ongoing Losses
•Equity Dilution

CLYM has strong liquidity and minimal debt, but persistent losses, negative cash flow, dilution, and a 3.36x book-value valuation make it a high-risk investment.

LiquidityStrength

ProfitabilityRisk

Price Behavior

5.0

Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

•Sharp reversal
•Average breakdown
•Neutral momentum

CLYM's strong last-month gain has been undermined by an 18% reversal below its moving average, so caution is warranted unless it reclaims $15.05–$16.40.

Caution

TechnicalSetup

Support Level: $14.00–$13.50

Resistance Level: $15.05–$16.40

18% drop from the $17.84 peak after a strong last-month rally